Moderator of 1 Session
Presenter of 1 Presentation
AΒETA OLIGOMER ELIMINATION IMPROVES COGNITION IN AGED BEAGLE DOGS - A MODEL OF SPORADIC ALZHEIMER’S DISEASE.
Abstract
Aims
Alzheimer´s Disease (AD) currently affects more than 24 million people worldwide, but to date, no curative or disease modifying treatment exists. During the last years, our group developed a drug candidate named RD2, which directly disassembles and destroys toxic Aβ oligomers, the Aβ species postulated to be responsible for the development and progression of AD. The aim of this study was to investigate the treatment efficacy of RD2 with regard to cognition and biomarkers in aged beagle dog - a model of sporadic AD -.
Methods
Aged beagle dogs were treated orally for three months with low or high doses of RD2 or placebo. Behavioral assessments were conducted longitudinally and CSF and plasma samples were collected at baseline and every month during the treatment period and during an additional two months after treatment discontinuation.
Results
Only RD2 treated dogs showed a significantly improved cognitive performance compared to baseline, even after the wash out period of two months.
Conclusions
We were able to show that RD2 significantly improves cognitive deficits in aged Beagle dogs. The maintenance of the cognitive improvement during the washout period even suggests a neuroprotective and truly disease-modifying effect of RD2.